生产企业：Shanghai SIMR Biotech Co., Ltd.
SRXXX (Epilepsy) is the placeholder designation for an undisclosed small-molecule drug candidate originated by Shanghai SIMR Biotech Co., Ltd. (上海赛默罗生物科技有限公司) for the treatment of epilepsy. The program is at the preclinical stage, and no clinical trials or regulatory approvals have been publicly registered for it to date. SIMR Biotech, founded in 2014 and headquartered in Shanghai, is an innovation-oriented biopharmaceutical company focused on discovering and developing new drugs for pain, inflammation and central nervous system diseases.
SRXXX (Epilepsy) is the placeholder designation for an undisclosed small-molecule drug candidate originated by Shanghai SIMR Biotech Co., Ltd. (上海赛默罗生物科技有限公司) for the treatment of epilepsy. The program is at the preclinical stage, and no clinical trials or regulatory approvals have been publicly registered for it to date. SIMR Biotech, founded in 2014 and headquartered in Shanghai, is an innovation-oriented biopharmaceutical company focused on discovering and developing new drugs for pain, inflammation and central nervous system diseases.
Epilepsy
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
